User login
Recent clinical trials of hormonal and endocrine therapies combined with chemotherapy have shown promise for patients with prostate cancer, according to Tomasz Beer, MD, of the Oregon Health and Science University.
“The landscape for prostate cancer therapy has really been evolving quite dramatically,” Dr. Beer said. “In 2005 we had the first life-extending chemotherapy; by 2011 we had 4 agents; and now we have 6 agents that shown an overall survival advantage.”
Recent clinical trials of hormonal and endocrine therapies combined with chemotherapy have shown promise for patients with prostate cancer, according to Tomasz Beer, MD, of the Oregon Health and Science University.
“The landscape for prostate cancer therapy has really been evolving quite dramatically,” Dr. Beer said. “In 2005 we had the first life-extending chemotherapy; by 2011 we had 4 agents; and now we have 6 agents that shown an overall survival advantage.”
Recent clinical trials of hormonal and endocrine therapies combined with chemotherapy have shown promise for patients with prostate cancer, according to Tomasz Beer, MD, of the Oregon Health and Science University.
“The landscape for prostate cancer therapy has really been evolving quite dramatically,” Dr. Beer said. “In 2005 we had the first life-extending chemotherapy; by 2011 we had 4 agents; and now we have 6 agents that shown an overall survival advantage.”
